enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hypoglossal nerve stimulator - Wikipedia

   en.wikipedia.org/wiki/Hypoglossal_nerve_stimulator

   The implant may be configured to best accommodate the patient's comfort and sleeping habits (e.g., set a delay based on sleep latency). The hypoglossal nerve stimulator implantable pulse generator battery life typically lasts 8–12 years, after which the implantable pulse generator may be safely replaced with another surgery. [8]

3. CPAP replacement works well for the overweight, not obese ...

   www.aol.com/implantable-alternative-cpap...

   To qualify for the device, called a hypoglossal nerve stimulator, a person over 18 diagnosed with moderate-to-severe obstructive sleep apnea must be unable to adapt or refuse to wear a continuous ...

4. Neuromodulation (medicine) - Wikipedia

   en.wikipedia.org/wiki/Neuromodulation_(medicine)

   Vagus nerve stimulation (VNS) [27] Hypoglossal nerve stimulation, an option for some patients who have obstructive sleep apnea [28] Percutaneous tibial nerve stimulation (PTNS) for the treatment of incontinence. Peripheral nerve stimulation (PNS, which refers to simulation of nerves beyond the spine or brain, and may be considered to include ...

5. Peripheral nerve interface - Wikipedia

   en.wikipedia.org/wiki/Peripheral_nerve_interface

   Peripheral nerve interfaces are used for pain modulation, [7] restoration of motor function following spinal cord injury or stroke, [8] treatment of epilepsy by electrical stimulation of the vagus nerve, [9] nerve stimulation to control micturition, occipital nerve stimulation for chronic migraines and to interface with neuroprosthetics.

6. Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U ...

   lite.aol.com/tech/story/0022/20240902/1000989628.htm

   Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device . FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024. U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised

7. Lilly's weight-loss treatment Zepbound becomes first FDA ...

   www.aol.com/news/lillys-weight-loss-drug-zep...

   Sleep apnea patients stop breathing briefly while sleeping, disturbing the sleep cycle and causing long-term complications such as heart conditions. The condition affects roughly one billion ...